TrialFrontiers in immunology2025

Neoadjuvant serplulimab and SOX chemotherapy for locally advanced gastric cancer: pathological responses and systemic immune signatures from a phase II trial.

Hongjie Zhan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.